The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing approval from U.S. regulators](

Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.

Yahoo Finance Executive Editor Brian Sozzi tracks some of Tuesday's trending tickers, including Novo Nordisk (NVO), Eli Lilly (LLY), D-Wave Quantum (QBTS), and Trump Media & Technology Group (DJT, DJTWW).

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — semaglutide — as the injectable Wegovy and Ozempic,

Novo Nordisk A/S (NYSE: NVO) is making headlines as a leading player in the weight-loss drug market, primarily due to its blockbuster medications, Ozempic and Wegovy. With projected sales reaching $17 billion in 2024 and over $14 billion in just the first nine months of 2025,

Tesla’s sales across the European Union, the Euro Free Trade Association and the UK dropped 11.8% year-on-year to 22,801 units in November, according to data released Tuesday by the European Automobile Manufacturers’ Association.

Dec 23 (Reuters) - European shares ‌were ​muted on ‌Tuesday as healthcare sector gains powered ​by heavyweight Novo Nordisk clinching U.S. ‍approval of its weight ​loss pill were offset ​by ⁠losses in consumer-facing shares.

​Novo Nordisk A/S (NYSE: NVO) is one of the Best Non-US Stocks to Buy According to Hedge Funds. On December 12, Novo Nordisk A/S (NYSE:NVO) announced receiving a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use for a higher dosage of Wegovy.